Related references
Note: Only part of the references are listed.Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Update on new biologics for intractable eosinophilic asthma: impact of reslizumab
Jagdeep Sahota et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
Jonathan Corren et al.
CHEST (2016)
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels A Randomized Phase 3 Study
Leif Bjermer et al.
CHEST (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Sally Wenzel et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Role of Interleukin-13 in Asthma
Jonathan Corren
CURRENT ALLERGY AND ASTHMA REPORTS (2013)
Mepolizumab treatment for asthma
Douglas S. Robinson
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Inhibiting Interleukin-4 and Interleukin-13 in Difficult-to-Control Asthma
Michael E. Wechsler
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Sally Wenzel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effect of Sch 55700, a Humanized Monoclonal Antibody to Human Interleukin-5, on Eosinophilic Responses and Bronchial Hyperreactivity
Robert Egan et al.
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH (2012)
Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor
N. A. Molfino et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Factors Associated With the Control of Severe Asthma
Juan Luis Rodriguez Hermosa et al.
JOURNAL OF ASTHMA (2010)
The cytokine network in asthma and chronic obstructive pulmonary disease
Peter J. Barnes
JOURNAL OF CLINICAL INVESTIGATION (2008)
Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment
Stephen P. Peters et al.
RESPIRATORY MEDICINE (2006)
Thymic stromal lymphopoietin: master switch for allergic inflammation
YJ Liu
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Can guideline-defined asthma control be achieved? The gaining optimal asthma control study
ED Bateman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
The role of T lymphocytes in the pathogenesis of asthma
M Larché et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
Share Paper
